Literature DB >> 26629282

Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2015        PMID: 26629282      PMCID: PMC4665051     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN: 1942-2962


× No keyword cloud information.
  6 in total

Review 1.  How I treat CLL up front.

Authors:  John G Gribben
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

2.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

Authors:  Richard R Furman; Jeff P Sharman; Steven E Coutre; Bruce D Cheson; John M Pagel; Peter Hillmen; Jacqueline C Barrientos; Andrew D Zelenetz; Thomas J Kipps; Ian Flinn; Paolo Ghia; Herbert Eradat; Thomas Ervin; Nicole Lamanna; Bertrand Coiffier; Andrew R Pettitt; Shuo Ma; Stephan Stilgenbauer; Paula Cramer; Maria Aiello; Dave M Johnson; Langdon L Miller; Daniel Li; Thomas M Jahn; Roger D Dansey; Michael Hallek; Susan M O'Brien
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

3.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Authors:  Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

4.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

Authors:  N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield
Journal:  J Clin Oncol       Date:  1999-12       Impact factor: 44.544

5.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

6.  Cost of illness and economic burden of chronic lymphocytic leukemia.

Authors:  Carl Rudolf Blankart; Taika Koch; Roland Linder; Frank Verheyen; Jonas Schreyögg; Tom Stargardt
Journal:  Orphanet J Rare Dis       Date:  2013-02-20       Impact factor: 4.123

  6 in total
  5 in total

1.  Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.

Authors:  Neeraj Jain; Satishkumar Singh; Georgios Laliotis; Amber Hart; Elizabeth Muhowski; Kristyna Kupcova; Tereza Chrbolkova; Tamer Khashab; Sayan Mullick Chowdhury; Anuvrat Sircar; Fazal Shirazi; Ram Kumar Singh; Lapo Alinari; Jiangjiang Zhu; Ondrej Havranek; Philip Tsichlis; Jennifer Woyach; Robert Baiocchi; Felipe Samaniego; Lalit Sehgal
Journal:  Blood Adv       Date:  2020-09-22

2.  Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.

Authors:  Ishwarya Murali; Siddha Kasar; Aishath Naeem; Svitlana Tyekucheva; Jasneet K Khalsa; Emily M Thrash; Gilad Itchaki; Dimitri Livitz; Ignaty Leshchiner; Shuai Dong; Stacey M Fernandes; Gad Getz; Amy Johnson; Jennifer R Brown
Journal:  Blood       Date:  2021-07-08       Impact factor: 25.476

3.  Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages.

Authors:  Evangelia Goulielmaki; Miriam Bermudez-Brito; Margarita Andreou; Niki Tzenaki; Maria Tzardi; Eelco de Bree; Eleftheria Tsentelierou; Antonis Makrigiannakis; Evangelia A Papakonstanti
Journal:  Cell Death Dis       Date:  2018-06-07       Impact factor: 8.469

Review 4.  Recent advances in chronic lymphocytic leukemia therapy.

Authors:  Jieun Uhm
Journal:  Blood Res       Date:  2020-07-31

Review 5.  FDA-Approved Drugs for Hematological Malignancies-The Last Decade Review.

Authors:  Aleksandra Sochacka-Ćwikła; Marcin Mączyński; Andrzej Regiec
Journal:  Cancers (Basel)       Date:  2021-12-24       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.